Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Dexamethasone. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR3C1 known ✓ | P04150 | 9/20 | 0.73 |
| ▸ | HIF1A | Q16665 | 8/20 | 0.73 |
| ▸ | CYP3A4 | P08684 | 7/20 | 0.73 |
| ▸ | HSD17B10 | Q99714 | 6/20 | 0.73 |
| ▸ | PGR | P06401 | 4/20 | 0.73 |
| ▸ | AR | P10275 | 3/20 | 0.73 |
| ▸ | NFKB1 | P19838 | 3/20 | 0.73 |
| ▸ | TSHR | P16473 | 2/20 | 0.73 |
| ▸ | NR3C2 | P08235 | 2/20 | 0.73 |
| ▸ | PMP22 | Q01453 | 2/20 | 0.73 |
| ▸ | MEN1 | O00255 | 1/20 | 0.73 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.73 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.73 |
| ▸ | APEX1 | P27695 | 1/20 | 0.73 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.73 |
| ▸ | IKBKB | O14920 | 1/20 | 0.73 |
| ▸ | CHUK | O15111 | 1/20 | 0.73 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.73 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.73 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.73 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Betamethasone SCHEMBL7070539 | 1.00 | NR3C1 (0.73) | NR3C1HIF1ACYP3A4HSD17B10PGR | |
| Clobetasol SCHEMBL2857967 | 0.96 | NR3C1 (0.67) | NR3C1HIF1ACYP3A4HSD17B10PGR | |
| Dexamethasone SCHEMBL20767432 | 0.95 | CYP3A4 (0.66) | NR3C1HIF1ACYP3A4HSD17B10PGR | |
| Triamcinolone SCHEMBL5151654 | 0.94 | HIF1A (0.72) | NR3C1HIF1ACYP3A4HSD17B10PGR | |
| Dexamethasone SCHEMBL4743981 | 0.94 | HSD17B10 (0.65) | NR3C1HIF1ACYP3A4HSD17B10PGR | |
| Dexamethasone SCHEMBL3877338 | 0.92 | CYP3A4 (0.69) | NR3C1HIF1ACYP3A4HSD17B10PGR | |
| Betamethasone SCHEMBL20576476 | 0.92 | CYP3A4 (0.69) | NR3C1HIF1ACYP3A4HSD17B10PGR | |
| Prednisolone Phosphoric Acid SCHEMBL7998176 | 0.92 | CYP3A4 (0.71) | NR3C1HIF1ACYP3A4HSD17B10PGR | |
| Flumethasone SCHEMBL7901450 | 0.92 | CYP3A4 (0.68) | NR3C1HIF1ACYP3A4HSD17B10PGR | |
| Prednisolone Phosphoric Acid SCHEMBL1930858 | 0.91 | CYP3A4 (0.69) | NR3C1HIF1ACYP3A4HSD17B10PGR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210335448-A1 | METHODS OF IDENTIFYING TREATMENTS USING DIFFERENTIALLY EXPRESSED GENES | Advaita Corporation (US) | 2021-10-28 | — | — | US | claimed |
| US-20040077562-A1 | Combination drug | NANDAN MOHAN CHANDAVARKAR (IN) | 2004-04-22 | — | — | US | claimed |
| US-20230310634-A1 | ANTI-HUMAN VISTA ANTIBODIES AND USE THEREOF | IMMUNEXT INC (US) | 2023-10-05 | — | — | US | disclosed |
| US-20230218567-A1 | COMPOUND AND METHOD FOR TREATING DISEASES AND DISORDERS | RCR BioPharma (US) | 2023-07-13 | — | — | US | disclosed |
| CN-115804907-A | Artificial cochlea drug-loading electrode and manufacturing, assembling and packaging methods thereof | 浙江诺尔康神经电子科技股份有限公司 | 2023-03-17 | — | — | CN | disclosed |
| EP-4136118-A1 | ANTI-HUMAN VISTA ANTIBODIES AND USE THEREOF | Immunext, Inc. (US) | 2023-02-22 | — | — | EP | disclosed |
| US-20210335448-A1 | METHODS OF IDENTIFYING TREATMENTS USING DIFFERENTIALLY EXPRESSED GENES | Advaita Corporation (US) | 2021-10-28 | — | — | US | disclosed |
| WO-2021216913-A1 | ANTI-HUMAN VISTA ANTIBODIES AND USE THEREOF | IMMUNEXT, INC. (US) | 2021-10-28 | — | — | WO | disclosed |
| US-20200061018-A1 | METHODS AND COMPOSITIONS FOR TREATING PARKINSON'S DISEASE | COVE BIO LLC (US) | 2020-02-27 | — | — | US | disclosed |
| CN-110753543-A | Methods and compositions for treating parkinson's disease | 海湾生物有限公司 | 2020-02-04 | — | — | CN | disclosed |
| EP-3554496-A1 | METHODS AND COMPOSITIONS FOR TREATING PARKINSON'S DISEASE | Cove Bio LLC (US) | 2019-10-23 | — | — | EP | disclosed |
| WO-2002045695-A2 | HYDROSTATIC DELIVERY SYSTEM FOR CONTROLLED DELIVERY OF AGENT | MACGREGOR ALEXANDER (CA) | 2002-06-13 | — | — | WO | disclosed |
| EP-0169105-B1 | CONTROLLED POROSITY OSMOTIC PUMP | MERCK & CO. INC. (US) | 1991-08-07 | — | — | EP | disclosed |
| US-4968507-A | SUSTAINED RELEASE OF DRUG | MERCK & CO., INC. (US) | 1990-11-06 | — | — | US | disclosed |
| EP-0208617-B1 | CONTROLLED DRUG DEVICE AND PROCESS FOR CATALYSING THE EROSION OF AN ACID LABILE POLYMER | MERCK & CO. INC. (US) | 1990-09-26 | — | — | EP | disclosed |
| WO-1989008119-A1 | HIGH MOLECULAR WEIGHT PRODRUG DERIVATIVES OF ANTI-INFLAMMATORY DRUGS | SELCH LARSEN CLAUS (DK) | 1989-09-08 | — | — | WO | disclosed |
| US-4851228-A | Multiparticulate controlled porosity osmotic | MERCK & CO., INC. (US) | 1989-07-25 | — | — | US | disclosed |
| US-4780319-A | DRUG DELIVERY USING POLYORTHOESTERS COATINGS | MERCK & CO., INC. (US) | 1988-10-25 | — | — | US | disclosed |
| EP-0208617-A1 | Controlled drug device and process for catalysing the erosion of an acid labile polymer | MERCK & CO. INC. (US) | 1987-01-14 | — | — | EP | disclosed |
| EP-0169105-A2 | Controlled porosity osmotic pump | MERCK & CO. INC. (US) | 1986-01-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230310634-A1 | ANTI-HUMAN VISTA ANTIBODIES AND USE THEREOF | CD47, CLTA, FCGR2A | NR3C1 104/4885HIF1A 2042/4885CYP3A4 3750/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.